Enspectra Health Announces US FDA Clearance of VIO‎™ System, 1st of Its Kind Technology to Visualize Skin Cellular Structures in Real-Time

Summation

  • “The cross-sectional images from VIO can be used to inform clinical decision-making in a variety of dermatological conditions in real-time which can have a powerful impact on clinical workflow and the patient journey.
  • The technology captures in vivo images of tissue – including blood vessels, collagen, pigment, stratum corneum, hair shafts or follicles, solar elastosis, hyperkeratosis, atypia, and epidermal disarray – in and through the epidermis, to assist physicians in forming a clinical judgment.
  • The VIO System was evaluated in the prospective, multicenter VISTA US Pivotal Study, demonstrating that it is safe and effective in a practical clinical environment.

Enspectra Health

Enspectra Health, a health tech company, announces US FDA 510(k) clearance of the VIO System, launching a new era in noninvasive imaging. VIO, the first of its kind technology, combines reflectance confocal and multiphoton microscopy to enable cellular resolution, cross-sectional imaging of skin in seconds. Easily portable and handheld, VIO digitizes pathology directly from a patient’s skin to provide clinical insights for physicians.

VIO System

“We are thrilled to receive FDA clearance for the VIO System. This is the first multiphoton imaging modality to ever be cleared by the FDA,” said Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health. “This significant achievement is the result of the excellent work by the Enspectra Health team and our clinical advisors. Our submission was cleared by the FDA ahead of plan, underscoring our ability to successfully drive an innovative technology from concept to clearance.”

The VIO System was evaluated in the prospective, multicenter VISTA US Pivotal Study, demonstrating that it is safe and effective in a practical clinical environment. The technology captures in vivo images of tissue – including blood vessels, collagen, pigment, stratum corneum, hair shafts or follicles, solar elastosis, hyperkeratosis, atypia, and epidermal disarray – in and through the epidermis, to assist physicians in forming a clinical judgment. VIO images are intended to be interpreted by dermatologists or pathologists with skin histology training. Physicians in the clinical study were able to identify skin features on VIO images with >90% average accuracy, exceeding study endpoints.

“The VIO System has tremendous potential for evaluating skin in clinical practice,” said Manu Jain, M.D., Memorial Sloan Kettering. “The cross-sectional images from VIO can be used to inform clinical decision-making in a variety of dermatological conditions in real-time which can have a powerful impact on clinical workflow and the patient journey.”

Limited Systems

Limited systems will be made available to select clinical partners. Enspectra Health plans to pursue additional indications and further advance its AI/ML clinical decision support algorithms.  For more information, please visit www.enspectrahealth.com.

About Enspectra Health: Enspectra Health is an emerging, privately held health tech company pioneering the virtual biopsy to transform the way physicians evaluate a broad spectrum of skin conditions. The Company’s novel technology combines reflectance confocal and multiphoton laser scanning microscopy to generate real-time, multispectral images at the cellular level, without the need for an incision. The technology allows for an instantaneous evaluation of rich, digital pathology images of various skin tissues, with the ultimate goal of minimizing unnecessary biopsies and facilitating earlier disease diagnosis.

Other FDA News of Interest

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy